Efficacy and Safety of Switching Between Certolizumab Pegol and Adalimumab after Primary Anti-TNF Treatment Failure: 2-Year Results from a Randomized, Investigator-Blind, Superiority Head-to-Head Study

被引：0

作者：

Fleischmann, Roy ^{[1
]}

Burmester, Gerd-Ruediger ^{[2
]}

Combe, Bernard ^{[3
]}

Curtis, Jeffrey R. ^{[4
]}

Hall, Stephen ^{[5
]}

Haraoui, Boulos ^{[6
]}

van Vollenhoven, Ronald ^{[7
]}

Cioffi, Christopher ^{[8
]}

Ecoffet, Cecile ^{[9
]}

Ionescu, Lucian ^{[10
]}

Gervitz, Leon ^{[11
]}

Peterson, Luke ^{[8
]}

Smolen, Josef ^{[12
,13
]}

机构：

[1] Univ Texas Southwestern Med Ctr Dallas, Metroplex Clin Res Ctr, Dallas, TX 75390 USA

[2] Charite Univ Med Berlin, Berlin, Germany

[3] Montpellier Univ Hosp, Montpellier, France

[4] Univ Alabama Birmingham, Birmingham, AL USA

[5] Monash Univ, Cabrini Med Ctr, Melbourne, Vic, Australia

[6] Ctr Hosp Univ Montreal, Dept Med, Montreal, PQ, Canada

[7] Amsterdam Rheumatol & Immunol Ctr ARC, Amsterdam, Netherlands

[8] UCB Pharma, Raleigh, NC USA

[9] UCB Pharma, Brussels, Belgium

[10] UCB Pharma, Allee Rech 60, Brussels, Belgium

[11] UCB Pharma, RA Patient Value Mission, Brussels, Belgium

[12] Med Univ Vienna, Vienna, Austria

[13] Hietzing Hosp, Vienna, Austria

来源：

ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

602

引用

页数：4

共 7 条

[1] Comparison of Certolizumab Pegol Versus Adalimumab: 2 Year Efficacy and Safety Results from a Superiority, Investigator-Blind, Head-to-Head Study
Fleischmann, Roy
Burmester, Gerd-Rudiger
Combe, Bernard
Curtis, Jeffrey R.
Hal, Stephen
Haraoui, Boulos
van Vollenhoven, Ronald
Cioffi, Christopher
Ecoffet, Cecile
Ionescu, Lucian
Gervitz, Leon
Peterson, Luke
Smolen, Josef
[J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
[2] Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study
Smolen, Josef S.
Burmester, Gerd-Ruediger
Combe, Bernard
Curtis, Jeffrey R.
Hall, Stephen
Haraoui, Boulos
van Vollenhoven, Ronald
Cioffi, Christopher
Ecoffet, Cecile
Gervitz, Leon
Ionescu, Lucian
Peterson, Luke
Fleischmann, Roy
[J]. LANCET, 2016, 388 (10061): : 2763 - 2774
[3] Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study (vol 388, pg 2763, 2016)
Smolen, J. S.
Burmester, G-R
Combe, B.
[J]. LANCET, 2016, 388 (10061): : 2742 - 2742
[4] Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study (vol 388, pg 2763, 2016)
Smolen, J. S.
Burmester, G-R
Combeet, B.
[J]. LANCET, 2017, 389 (10068): : E2 - E2
[5] EFFICACY AND SAFETY OF PATECLIZUMAB (ANTI-LYMPHOTOXIN-ALPHA) IN DMARD-IR PATIENTS: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED HEAD-TO-HEAD PHASE 2 STUDY WITH ADALIMUMAB
Kennedy, W.
Horn, P.
Su, Z.
Basu, K.
Herman, A.
Song, A.
Townsend, M.
Xiao, J.
Grogan, J.
Derby, M.
Simon-Campos, J. A.
Davis, J., Jr.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 617 - 618
[6] Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study
Boonen, Steven
Lorenc, Roman S.
Wenderoth, Dietrich
Stoner, Karen J.
Eusebio, Rachelle
Orwoll, Eric S.
[J]. BONE, 2012, 51 (03) : 383 - 388
[7] Long-term Maintenance of Remission with No Dose Escalation After Re-induction with Certolizumab Pegol in Patients with Crohn's Disease Exacerbation Who Were Naive to Anti-TNF Treatment: 4-Year Results from the PRECiSE 4 Study
Sandborn, William
Schreiber, Stefan
Hanauer, Stephen
Colombel, Jean-Frederic
Bloomfield, Ralph
Lichtenstein, Gary
[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S418 - S418

← 1 →